Executive Committee

The Executive Committee supports the day-to-day decisions of the Managing Director of the Therapeutics Initiative.

Terms of Reference

  1. The Executive Committee consists of several members in addition to the Managing Director(s). The other members represent the chairs of the working groups and other members representing other functions. The members of the Executive Committee are recommended to the Scientific Information and Education Committee by the Managing Director(s) for appointment to three-year renewable terms.
  2. The Executive Committee meets between the meetings of the Scientific Information and Education Committee as necessary to support the operations of the Therapeutics Initiative and the associated contracts for service.
  3. The Executive Committee identifies and nominates new members for the Scientific Information and Education Committee.

Membership of the Executive Committee

Dr. James M. Wright, M.D., Ph.D., FRCP(C)

Dr Jim WrightCo-Managing Director and Chair, Therapeutics Initiative
Professor, Departments of Anesthesiology, Pharmacology & Therapeutics and Medicine, UBC
Clinical Pharmacologist, Vancouver Hospital
Coordinating Editor, Cochrane Hypertension Review Group

James (Jim) Wright is a Professor in the Departments of Anesthesiology, Pharmacology & Therapeutics and Medicine at the University of BC, Vancouver, Canada. He obtained his MD from the University of Alberta in 1968, his FRCP(C) in Internal Medicine in 1975 and his Ph.D. in Pharmacology from McGill University in 1976. He is a practicing specialist in Internal Medicine and Clinical Pharmacology. He is also Managing Director of the Therapeutics Initiative, Editor-in-Chief of the Therapeutics Letter and Coordinating Editor of the Cochrane Hypertension Review Group. He sits on the Editorial Boards of the following journals: Open Medicine, PLoS One and the Cochrane Library. Dr. Wright's research focuses on issues related to appropriate use of prescription drugs, Clinical Pharmacology, clinical trials, systematic review, meta-analysis and knowledge translation.
No conflict of interest declared | See TI conflict of interest policy

 

 

Dr. Ken Basset, M.D., Ph.D.

Dr Ken Bassett

Co-Managing Director, Therapeutics Initiative
Professor, Departments of Family Practice and Anesthesiology, Pharmacology & Therapeutics, UBC
Faculty Member, Centre for Health Services & Policy Research, UBC
Associate Member, Departments of Ophthalmology, UBC and Health Care and Epidemiology, UBC

Ken Bassett conducts systematic reviews of the efficacy and safety of new and established drugs, as well as pharmaco-epidemiologic studies of serious adverse events associated with prescription drug therapy in British Columbia. His ongoing research interests are in the systematic review of drug therapy and drug funding policy.
No conflict of interest declared | See TI conflict of interest policy

 

 

Dr. Colin Dormuth, M.Sc., Sc.D.

Dr Colin Dormuth

Assistant Professor, Dept of Anesthesiology, Pharmacology & Therapeutics, UBC
Chair, Pharmaco-Epidemiology Working Group, Therapeutics Initiative 

Colin Dormuth has 13 years of experience using administrative health care databases to evaluate pharmaceutical policy changes and physician prescribing behaviour. He has been a member of the Therapeutics Initiative since 1995. His research focuses on drug safety and effectiveness, as well as the design and evaluation of reimbursement policies for prescription drugs. He has training in economic theory, applied econometrics, epidemiology, health services outcome research and biostatistics. Dr. Dormuth holds a Sc.D. and S.M. in epidemiology from Harvard University, an M.A. in economics from the University of Victoria, and a B.A. in economics from the University of Manitoba.
No conflict of interest declared | See TI conflict of interest policy

 

 

Dr. Barbara Mintzes, B.Sc., Ph.D.

Dr Barbara Mintzes

Assistant Professor, Dept of Anesthesiology, Pharmacology & Therapeutics, UBC
Michael Smith Foundation for Health Research Scholar

Barbara Mintzes holds a BA in geography from Simon Fraser University and a PhD in health care and epidemiology from the University of British Columbia. She carries out evaluations of drug safety and effectiveness that provide background information for provincial drug financing decisions. She also works as a clinical reviewer with the Common Drug Review.
The focus of her research is pharmaceutical policy, and her main area of expertise is on the effects of direct-to-consumer advertising of prescription drugs on prescribing and medicine use. She is also involved in research on the influence of regulatory standards for drug promotion on the quality of information provided. She coordinates a global research project on rational use of medicines with Health Action International, a network of consumer, health and development organizations representing public interests in pharmaceutical policy, and is involved in a collaborative World Health Organization project to develop curriculum for pharmacy and medical students on drug promotion and interactions with the industry. She also works with the Pharmaceutical Policy Unit at UBC’s Centre for Health Services and Policy Research, and is a member of the Steering Group of Women and Health Protection.

No conflict of interest declared | See TI conflict of interest policy

 

 

Dr. Vijaya Musini, M.D., M.Sc., M.Sc.   

Assistant Professor, Dept of Anesthesiology, Pharmacology & Therapeutics, UBC
Manager, Drug Assessment Working Group, Therapeutics Initiative

Vijaya Musini has conducted and supervised over 200 systematic reviews and meta-analyses on prescription drug therapy. She is an Editor of the Cochrane Hypertension Review Group and has been actively involved in teaching Cochrane Collaboration systematic review methodology and critical appraisal skills on evidence based drug therapy to undergraduate, graduate, medical students and residents. Dr. Musinigraduated from Mumbai University Medical School in 1982. After completing her rotating internship she joined the Department of Community Medicine in 1984 and graduated with a Diploma in Public Health from Mumbai University Medical School in 1985. She has worked as a Family Practitioner and as a Medical Officer in primary health care centres in Mumbai, India for several years. She also worked as a research assistant in the Departments of Gynaecology and Obstetrics, and Health Care and Epidemiology, Faculty of Medicine, Kuwait University. She immigrated to Canada in 1996 and graduated with a Masters Degree in Pharmacology and Therapeutics from the University of British Columbia in 2000.
No conflict of interest declared | See TI conflict of interest policy

 

Dr. Thomas Perry jr, M.D., FRCP

Dr Tom Perry

Clinical Assistant Professor, Department of Medicine, UBC
Clinical Pharmacologist, General Internist, Vancouver Hospital
Chair, Education Working Group, Therapeutics Initiative

Thomas L. Perry graduated from McGill University Medical School in 1978. After a rotating internship at Dalhousie University, he started a residency in general internal medicine at UBC, broken by 2 years of locum tenens general practice in isolated communities in B.C., Yukon, and Ontario. After completing his specialty residency and achieving Fellowship in the Royal College of Physicians of Canada, he spent one year on a Medical Research Council fellowship studying metabolism of tricyclic antidepressants with Dr. Leif Bertilsson at the Karolinska Institute Department of Clinical Pharmacology in Stockholm, and a further 2 years at UBC's Department of Pharmacology & Therapeutics. Dr. Perry was then elected to the Legislative Assembly of B.C. where he served as Opposition Health Critic from 1989-1991, as Minister for Advanced Education, Training & Technology from 1991-93, and as a government MLA from 1993-96.
Dr. Perry returned to clinical medicine in 1996 and now practices general internal medicine at UBC Hospital and Vancouver General Hospital. He teaches internal medicine in the Department of Medicine Clinical Teaching Unit program at VGH and clinical pharmacology through seminars, lectures and elective student clinical training at UBCH. His outpatient practice focuses on pharmacological treatment of chronic pain and high blood pressure. He has a special interest in the use of videography to teach students and doctors about drugs. He is the Chair of the Education Working Group, member of the Drug Assessment Working Group, member of the SIEC and participates frequently in the development of TI Letters.
Dr. Perry's other interests include wilderness canoeing and hiking, environmental conservation, peace and social justice, music, reading, and his family.

Conflict of Interest: Dr. Perry has consulted on a paid basis for Greene & Hoffman (attorneys) of Boston, MA, USA as an expert consultant in clinical pharmacology for a proposed class-action lawsuit against Pfizer Inc. with respect to Neurontin (gabapentin), paid on an hourly rate not contingent upon his opinion. Dr. Perry is a frequent clinical pharmacologic medical legal consultant to the Canadian Medical Protective Association (CMPA) and to the Insurance Corporation of B.C. (ICBC), and occasionally to other defence or plaintiff laywers in medical legal litigation, paid on an hourly rate, where the rate and payment are not contingent upon his opinion. See TI conflict of interest policy

 

Dr. Aaron Tejani, B.Sc(Pharm), Pharm.D, ACPR

Dr Aaron Tejani

Coordinator, Clinical Research and Drug Information Fraser Health Pharmacy Services Researcher, Drug Assessment Working Group, Therapeutics Initiative

Aaron Tejani completed his BSc in pharmaceutical sciences at the University of British Columbia and his Doctor of Pharmacy degree from Creighton University (Omaha, Nebraska). Aaron’s interests include criticall appraisal of the biomedical literature, knowledge translation activities and research, and conducting systematic reviews and meta-analyses of health care interventions. He is also involved in teaching critical appraisal skills to undergraduate and graduate students, as well as health care professionals. He is currently: a member of the Fraser Health Research Ethics Board and the British Columbia Medical Association’s Guidelines and Protocols Advisory Committee, an editor for the Cochrane Hypertension Review Group, a peer reviewer for the Canadian Journal of Emergency Medicine, and a clinical instructor for the Faculty of Pharmaceutical Sciences (University of British Columbia). Within the Therapeutics Initiative, he is a member of the Drug Assessment Working Group, the Education Working Group, and the Scientific Information and Education Committee.
No conflict of interest declared | See TI conflict of interest policy

 

 

Dr. Casey van Breemen, D.V.M., M.Sc., Ph.D.

Dr Casey van Breemen

Emeritus Professor, Dept of Anesthesiology, Pharmacology & Therapeutics, UBC 

Cornelis (Casey) van Breemen received his DVM at the Ontario Veterinary College in 1960, pursued clinical veterinary medicine for one year before enrolling as a graduate student at the University of Alberta where he earned an MSc in Physiology in 1962 and a PhD in Pharmacology in 1965. He subsequently did post-doctorate studies in the Department of Polymer Scienes at the Weizman Institute, Israel and the Department of Physiology at the University of Leicester, UK. In 1967 he was appointed Assistant Professor in Pharmacology at the University of Florida and in 1969 moved to the University of Miami where he was promoted to Professor of Pharmacology in 1977. In 1993 he was recruited by UBC as Head of the Department of Pharmacology & Therapeutics from where he officially retired in 2002, but continued on his productive research career (over 250 publications) in the area of vascular physiology and pharmacology. From the early sixties to the present Dr. van Breemen has investigated the signaling systems within blood vessels, both of the endothelium and smooth muscle. At present his laboratory focuses on the critical role of nanodomains resulting from complex membrane ultra-structure in vascular control in health and diseases such as Marfan Syndrome and Diabetes. He has trained many successful graduate students and post-doctorate fellows. He has received several distinctions and awards:
• Established Investigator for the American Heart Association, 1972
• Invited visiting Professor at the University of Louvain, 1972
• Sigma-Xi, University of Miami, Professor of the Year, 1991
• Alexander von Humboldt Foundation Senior, US Scientist Award, 1992
• Distinguished Lecturer, Faculty of Medicine, The University of British Columbia, 1995
• Ciba-Geigy Canada Ltd., Prestigious Award for Outstanding Contributions to Pharmacology in Canada, Pharmacological Society in Canada, Bath, UK, July 1996
• UBC Killam Research Prize for 1997
• Invited distinguished professor at Universidad Complutense, Madrid, Spain

No conflict of interest declared | See TI conflict of interest policy